BREAKING
Monte Rosa (GLUE) Reports Wider Q4 Loss of $0.55/Share vs $0.34 Estimate, Revenue Misses 9 minutes ago Monte Rosa Therapeutics, Inc. (GLUE) Reports Wider Loss Q4 EPS Estimates by 63.4% 13 minutes ago Coda Octopus (CODA) Beats Q1 Estimates with $0.08 EPS, Revenue Surges 28.6% YoY to $6.7M 24 minutes ago Bicycle Therapeutics (BCYC) Q4 Revenue Soars 1194.5% YoY to $48M, Crushing Estimates by 578% 26 minutes ago Getty Images (GETY) Q4 Revenue Surges 14.1% YoY to $282.3M 47 minutes ago FINV Stock: 8 Analysts Issue Buy-or-Better Ratings as FinVolution Delivers $0.25 EPS on Flat Revenue 1 hour ago Semtech (SMTC) Beats Q4 EPS Estimates by 2.0% with $0.44 Earnings, Revenue Climbs 9.3% YoY 1 hour ago Dragonfly Energy (DFLI) Posts $14.92 Loss Per Share for Q4, Revenue at $13.1M 1 hour ago Microvast (MVST) Q4 Revenue Falls 15% to $96.4M, Adjusted EPS Loss of $0.11 Misses Estimates 2 hours ago BW Swings to Profit with $0.05 EPS, Beating Estimates by 134.4% on $161M Revenue 2 hours ago Monte Rosa (GLUE) Reports Wider Q4 Loss of $0.55/Share vs $0.34 Estimate, Revenue Misses 9 minutes ago Monte Rosa Therapeutics, Inc. (GLUE) Reports Wider Loss Q4 EPS Estimates by 63.4% 13 minutes ago Coda Octopus (CODA) Beats Q1 Estimates with $0.08 EPS, Revenue Surges 28.6% YoY to $6.7M 24 minutes ago Bicycle Therapeutics (BCYC) Q4 Revenue Soars 1194.5% YoY to $48M, Crushing Estimates by 578% 26 minutes ago Getty Images (GETY) Q4 Revenue Surges 14.1% YoY to $282.3M 47 minutes ago FINV Stock: 8 Analysts Issue Buy-or-Better Ratings as FinVolution Delivers $0.25 EPS on Flat Revenue 1 hour ago Semtech (SMTC) Beats Q4 EPS Estimates by 2.0% with $0.44 Earnings, Revenue Climbs 9.3% YoY 1 hour ago Dragonfly Energy (DFLI) Posts $14.92 Loss Per Share for Q4, Revenue at $13.1M 1 hour ago Microvast (MVST) Q4 Revenue Falls 15% to $96.4M, Adjusted EPS Loss of $0.11 Misses Estimates 2 hours ago BW Swings to Profit with $0.05 EPS, Beating Estimates by 134.4% on $161M Revenue 2 hours ago
ADVERTISEMENT
Breaking News

Monte Rosa Therapeutics, Inc. (GLUE) Reports Wider Loss Q4 EPS Estimates by 63.4%

Monte Rosa Therapeutics, Inc. (GLUE) reported Q4 2025 GAAP loss of $0.55 per share, a wider loss than the -$0.34 estimate (63.4% wider).

March 17, 2026 1 min read

Monte Rosa Therapeutics, Inc. (GLUE) reported Q4 2025 GAAP loss of $0.55 per share, a wider loss than the -$0.34 estimate (63.4% wider).

Shares traded at $16.02. on volume of 616,447. The company has a market capitalization of $1.25B.

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectivel…

A detailed analysis of Monte Rosa Therapeutics, Inc.’s quarter follows shortly on AlphaStreet.

This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.

ADVERTISEMENT
Tags: #GLUE